- Home
- ARDX vs SAVA Comparison
ARDX vs SAVA Comparison
Compare ARDX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- SAVA
- Stock Information
- Founded
- ARDX 2007
- SAVA 1998
- Country
- ARDX United States
- SAVA United States
- Employees
- ARDX N/A
- SAVA N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ARDX Health Care
- SAVA Health Care
- Exchange
- ARDX Nasdaq
- SAVA Nasdaq
- Market Cap
- ARDX 1.4B
- SAVA 1.3B
- IPO Year
- ARDX 2014
- SAVA N/A
- Fundamental
- Price
- ARDX $5.11
- SAVA $27.65
- Analyst Decision
- ARDX Buy
- SAVA Strong Buy
- Analyst Count
- ARDX 7
- SAVA 3
- Target Price
- ARDX $11.75
- SAVA $111.50
- AVG Volume (30 Days)
- ARDX 5.8M
- SAVA 1.6M
- Earning Date
- ARDX 10-31-2024
- SAVA 11-07-2024
- Dividend Yield
- ARDX N/A
- SAVA N/A
- EPS Growth
- ARDX N/A
- SAVA N/A
- EPS
- ARDX N/A
- SAVA N/A
- Revenue
- ARDX $251,849,000.00
- SAVA N/A
- Revenue This Year
- ARDX $167.24
- SAVA N/A
- Revenue Next Year
- ARDX $18.93
- SAVA N/A
- P/E Ratio
- ARDX N/A
- SAVA N/A
- Revenue Growth
- ARDX 87.57
- SAVA N/A
- 52 Week Low
- ARDX $4.06
- SAVA $8.79
- 52 Week High
- ARDX $10.13
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- ARDX 44.65
- SAVA 64.80
- Support Level
- ARDX $4.63
- SAVA $25.72
- Resistance Level
- ARDX $5.24
- SAVA $29.49
- Average True Range (ATR)
- ARDX 0.42
- SAVA 2.63
- MACD
- ARDX -0.00
- SAVA 0.48
- Stochastic Oscillator
- ARDX 35.59
- SAVA 82.89
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.